MRPS23 and breast carcinoma: After 10 years of follow-up, patients with MRPS23 amplified tumours had 40% (95% CI 27–56) cumulative risk of death from breast cancer, compared to 30% (95% CI 27–34) for patients without amplification (Table 4; Fig. 3c).